Celgene Corp. to pay $280M to settle cancer drug fraud suit
A New Jersey pharmaceutical company has agreed to pay $280 million to settle a federal lawsuit alleging it committed fraud promoting two cancer drugs for unapproved purposes.
from Biotech News
0 Comments